An Open-Label, Crossover Study to Determine the Pharmacokinetic Profile and Tolerability of Single Doses of High Strength Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler Compared to High Strength FLOVENT DISKUS and ADVAIR DISKUS in Patients With Persistent Asthma 12 Years of Age and Older

Trial Profile

An Open-Label, Crossover Study to Determine the Pharmacokinetic Profile and Tolerability of Single Doses of High Strength Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler Compared to High Strength FLOVENT DISKUS and ADVAIR DISKUS in Patients With Persistent Asthma 12 Years of Age and Older

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs Fluticasone propionate (Primary) ; Salmeterol/fluticasone propionate (Primary)
  • Indications Asthma
  • Focus Pharmacokinetics
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 06 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top